ProCE Banner Activity

CROI 2019: Results From the DISCOVER Trial and Implications for HIV PrEP in Germany

Conference Coverage
Clinical Thought
New data on FTC/TAF demonstrate noninferior HIV prevention efficacy vs FTC/TDF as daily oral PrEP among cis-MSM and transgender women. What do these results mean in the context of new German legislation around reimbursement for PrEP?

Released: April 05, 2019

Expiration: April 03, 2020

No longer available for credit.

Share

Faculty

Jürgen K. Rockstroh

Jürgen K. Rockstroh, MD

Head of Infectious Diseases
Professor of Medicine 
University Hospital Bonn
Bonn, Germany  

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This program is supported by independent educational grants from

Gilead Text

ViiV Healthcare

Faculty Disclosure

Primary Author

Jürgen K. Rockstroh, MD

Head of Infectious Diseases
Professor of Medicine 
University Hospital Bonn
Bonn, Germany  

Jürgen K. Rockstroh, MD, has disclosed that he has received consulting fees from Abivax, Gilead Sciences, Janssen, Merck, and ViiV and funds for research support from AbbVie, Gilead Sciences, Janssen, Merck, and Siemens.